Skip to main content

U.S. FDA OKs Regeneron COVID-19 antibody as preventive in high-risk settings

Share

The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

The company said the authorization enables the therapy to be used in people exposed to an infected individual, or who are at high risk of exposure to an infected individual in settings such as nursing homes or prisons.

The combo therapy, REGEN-COV, was authorized in November for emergency use to treat people with mild-to-moderate COVID-19 in the United States.

REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company in April.

Regeneron said the expanded authorization will help address the needs of immunocompromised people, including those taking immunosuppressive medicines, whose bodies may not mount an adequate response to COVID-19 vaccination.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)

CTVNews.ca Top Stories

OPINION

OPINION What King Charles' schedule being too 'full' to accommodate son suggests

Prince Harry, the Duke of Sussex, has made headlines with his recent arrival in the U.K., this time to celebrate all things Invictus. But upon the prince landing in the U.K., we have already had confirmation that King Charles III won't have time to see his youngest son during his brief visit.

Local Spotlight

Stay Connected